Dysfunction of the hypothalamic-pituitary-adrenal axis in opioid dependent subjects: Effects of acute and protracted abstinence

American Journal of Drug and Alcohol Abuse

Volumn 34, Issue 6, 2008, Pages 760-768

  Zhang, Guo Fu ^a   Ren, Yan Ping ^a   Sheng, Li Xia ^a   Chi, Yong ^a   Du, Wan Jun ^a   Guo, Song ^a   Jiang, Zuo Ning ^a   Xiao, Le ^a   Luo, Xiao Nian ^a   Tang, Yi Lang ^b   Smith, Alicia K ^b   Liu, Zhen Qi ^c   Zhang, Hong Xi ^d  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^d Tianjin Ankang Hospital   (China)

Author keywords

ACTH; Cortisol; CRH; HPA axis; Opioid dependence

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CLONAZEPAM; CLONIDINE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; DIAMORPHINE; ESTAZOLAM; HYDROCORTISONE; LORAZEPAM; METHADONE; OPIATE;

ADULT; ARTICLE; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; HEROIN DEPENDENCE; HORMONE RESPONSE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; OPIATE ADDICTION;

ADRENOCORTICOTROPIC HORMONE; ADULT; BENZODIAZEPINES; CLONIDINE; CORTICOTROPIN-RELEASING HORMONE; FEMALE; HEROIN DEPENDENCE; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; METHADONE; PITUITARY-ADRENAL SYSTEM; SUBSTANCE WITHDRAWAL SYNDROME; YOUNG ADULT;

EID: 56549116540     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.1080/00952990802385781     Document Type: Article

References (18)

1. Houshyar H, Galigniana MD, Pratt WB, Woods JH. Differential responsivity of the hypothalamic-pituitary-adrenal axis to glucocorticoid negative-feedback and corticotropin releasing hormone in rats undergoing morphine withdrawal: possible mechanisms involved in facilitated and attenuated stress responses. J Neuroendocrinol 2001; 13(10):875-886.
2. Houshyar H, Cooper ZD, Woods JH. Paradoxical effects of chronic morphine treatment on the temperature and pituitary-adrenal responses to acute restraint stress: A chronic stress paradigm. J Neuroendocrinol 2001; 13(10):862-874.
3. Gerra G, Ceresini S, Esposito A, Zaimovic A, Moi G, Bussandri M, Raggi MA, Molina E. Neuroendocrine and behavioural responses to opioid receptor-antagonist during heroin detoxification: Relationship with personality traits. Int Clin Psychopharmacol 2003; 18(5):261-269.
4. Schluger JH, Borg L, Ho A, Kreek MJ. Altered HPA axis responsivity to metyrapone testing in methadone maintained former heroin addicts with ongoing cocaine addiction. Neuropsychopharmacology 2001; 24(5):568-575.
5. Jiang ZN. Heroin Addiction and Contemporary Treatments. 1st Ed. Beijing: Science Press, 1995.
6. Vale W, Vaughan J, Yamamoto G, Bruhn T, Douglas C, Dalton D, Rivier C, Rivier J. Assay of corticotropin releasing factor. Methods Enzymol 1983; 103:565-577.
7. Ziolkowska A, Budzynska K, Trejter M, Tortorella C, Belloni AS, Malendowicz LK. Effects of adrenomedullin and its fragment 22-52 on basal and ACTH-stimulated secretion of cultured rat adrenocortical cells. Int J Mol Med 2003; 11(5):613-615.
8. Kennedy DM, Selby C, Lawson N. Measurement of urinary free cortisol using the Acs: 180 serum cortisol chemiluminescent immunoassay. Ann Clin Biochem 2000; 37(Pt4):520-528.
9. Tang YL, Zhao D, Zhao C, Cubells JF. Opiate addiction in China: Current situation and treatments. Addiction 2006; 101(5):657-665.
10. Milanes MV, Laorden ML, Chapleur-Chateau M, Burlet A. Differential regulation of corticotropin-releasing factor and vasopressin in discrete brain regions after morphine administration: Correlations with hypothalamic noradrenergic activity and pituitary-adrenal response. Naunyn Schmiedebergs Arch Pharmacol 1997; 356(5):603-610.
11. Kanchev LN, Baichev J, Kamenov I, Baikov B, Hallak AK, Melatonin, corticosterone, stress and phygocytic activity. Bulgarian J Veterinary Medicine 2006; 9(4):257-264.
12. Contoreggi C, Herming RI, Na P, Gold PW, Chrousos G, Negro PJ, Better W, Cadet JL. Stress hormone responses to corticotropin-releasing hormone in substance abusers without severe comorbid psychiatric disease. Biol Psychiatry 2003; 54(9):873-878.
13. Nava F, Caldiroli E, Premi S, Lucchini A. Relationship between plasma cortisol levels, withdrawal symptoms and craving in abstinent and treated heroin addicts. J Addictive Diseases 2006; 25(2):9-16.
14. Pechnick RN. Effects of opioids on the hypothalamo-pituitary-adrenal axis. Annu Rev Pharmacol Toxicol 1993; 33:353-382.
15. Maj M, Turchan J, Smialowska M, Przewlocka B. Morphine and cocaine influence on CRF biosynthesis in the rat central nucleus of amygdala. Neuropeptides 2003; 37(2):105-110.
16. Milanes MV, Laorden ML, Angel E, Tankosic P, Burlet A. Effect of naloxone-precipitated morphine withdrawal on CRH and vasopressin mRNA expression in the rat hypothalamic paraventricular nucleus. Neurosci Lett 2002; 334(1):58-62.
17. Hinz B, Hirschelmann R. Rapid non-genomic feedback effects of glucocorticoids on CRF-induced ACTH secretion in rats. Pharm Res 2000; 17(10):1273-1277.
18. Slominski A, Zbytek B, Zmijewski M, Slominski RM, Kauser S, Wortsman J, Tobin DJ. Corticotropin releasing hormone and the skin. Front Biosci 2006; 11:2230-2248.